Explore

Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy
Trendline Trendline
AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Cellular Intelligence Licenses Novo Nordisk's Parkinson's Cell Therapy for AI-Enhanced Development

Cellular Intelligence Licenses Novo Nordisk's Parkinson's Cell Therapy for AI-Enhanced Development

Cellular Intelligence Licenses Novo Nordisk's Parkinson's Cell Therapy for AI-Enhanced Development
Trendline Trendline
Novo Nordisk's microRNA Drug Fails to Show Benefit in Heart Failure Trial

Novo Nordisk's microRNA Drug Fails to Show Benefit in Heart Failure Trial

Novo Nordisk's microRNA Drug Fails to Show Benefit in Heart Failure Trial
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates

BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates

BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Challenges in Phase 3 Trial

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Challenges in Phase 3 Trial

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Challenges in Phase 3 Trial
Trendline Trendline
Forge Biologics to Present Gene Therapy Advancements at ASGCT Annual Meeting

Forge Biologics to Present Gene Therapy Advancements at ASGCT Annual Meeting

Forge Biologics to Present Gene Therapy Advancements at ASGCT Annual Meeting